<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELESTAT- epinastine hydrochloride solution/ drops </strong><br>Allergan, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ELESTAT<span class="Sup">®</span> safely and effectively.  See full prescribing information for ELESTAT<span class="Sup">®</span>.  <br>ELESTAT<span class="Sup">®</span> (epinastine HCl ophthalmic solution) 0.05%<br>Initial U.S. Approval: 2003
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"><span class="Bold">ELESTAT</span><span class="Sup">®</span> is an H<span class="Sub">1</span> histamine receptor antagonist indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>. (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended dosage is one drop in each eye twice a day. (<a href="#s2">2</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Ophthalmic solution containing 0.5 mg/mL epinastine HCl. (<a href="#s3">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#s4">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>To minimize the risk of contamination, do not touch dropper tip to any surface. Keep bottle tightly closed when not in use. (<a href="#s6">5.1</a>)
</li>
<li>
<span class="Bold">ELESTAT</span><span class="Sup">®</span> should not be used to treat contact lens-related irritation. (<a href="#s7">5.2</a>)
</li>
<li>Remove contact lenses prior to instillation of <span class="Bold">ELESTAT</span><span class="Sup">®</span>. (<a href="#s7">5.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common ocular adverse reactions (incidence occurring in approximately 1% - 10% of <span class="Bold">ELESTAT</span><span class="Sup">®</span> treated eyes were <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> in the eye, folliculosis, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>. The most common non-ocular adverse reactions, occurring in 10% of <span class="Bold">ELESTAT</span><span class="Sup">®</span> treated eyes, were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">cold symptoms</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span>). (<a href="#s10">6.1</a>)
 </p>
<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Contamination of Tip and Solution
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Use with Contact Lenses
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Topical Ophthalmic Use Only
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip
</a></h2>
<h2><a href="#section-13.2" class="toc">17.2 Concomitant Use of Contact Lenses
</a></h2>
<h2><a href="#section-13.3" class="toc">17.3 Topical Ophthalmic Use Only
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">ELESTAT</span><span class="Sup">®</span> ophthalmic solution is indicated for the prevention of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The recommended dosage is one drop in each eye twice a day.
</p>
<p>Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Solution containing 0.5 mg/mL epinastine HCl
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">None
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Contamination of Tip and Solution
</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.
</p>
<p>Bottle should be kept tightly closed when not in use.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Use with Contact Lenses
</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. <span class="Bold">ELESTAT</span><span class="Sup">®</span> ophthalmic solution should not be used to treat contact lens-related irritation.
</p>
<p>The preservative in <span class="Bold">ELESTAT</span><span class="Sup">®</span>, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed prior to instillation of <span class="Bold">ELESTAT</span><span class="Sup">®</span> ophthalmic solution and may be reinserted after 10 minutes following its administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Topical Ophthalmic Use Only
</h2>
<p class="First"><span class="Bold">ELESTAT</span><span class="Sup">®</span> is for topical ophthalmic use only and not for injection or oral use.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
</p>
<p>The most frequently reported ocular adverse reactions occurring in approximately 1-10% of patients were <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> in the eye, folliculosis, <span class="product-label-link" type="condition" conceptid="4146766" conceptname="Hyperemia">hyperemia</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.
</p>
<p>The most frequently reported non-ocular adverse reactions were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">cold symptoms</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span>), seen in approximately 10% of patients, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, seen in approximately 1 - 3% of patients.
</p>
<p>Some of these reactions were similar to the underlying disease being studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following reactions have been identified during postmarketing use of <span class="Bold">ELESTAT</span><span class="Sup">®</span> in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to <span class="Bold">ELESTAT</span><span class="Sup">®</span>, or a combination of these factors, include: <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation increased</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="e13"></a><a name="section-7.1.1"></a><p></p>
<p class="First">Teratogenic Effects<br>Pregnancy Category C
</p>
<p>In an embryofetal developmental study in pregnant rats, maternal toxicity with no embryofetal effects was observed at an oral dose that was approximately 150,000 times the maximum recommended ocular human dose (MROHD) of 0.0014 mg/kg/day on a mg/kg basis. Total resorptions and abortion were observed in an embryofetal study in pregnant rabbits at an oral dose that was approximately 55,000 times the MROHD. In both studies, no drug-induced teratogenic effects were noted.
</p>
<p>Epinastine reduced pup body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> following an oral dose to pregnant rats that was approximately 90,000 times the MROHD.
</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, <span class="Bold">ELESTAT</span><span class="Sup">®</span> ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">A study in lactating rats revealed excretion of epinastine in the breast milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when <span class="Bold">ELESTAT</span><span class="Sup">®</span> ophthalmic solution is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s17"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First"><span class="Bold">ELESTAT</span><span class="Sup">®</span> (epinastine HCl ophthalmic solution) 0.05% is a clear, colorless, sterile isotonic solution containing epinastine HCl, an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes.
</p>
<p>Epinastine HCl is represented by the following structural formula:
</p>
<p><a name="f01"></a><img alt="structural formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9628ec7-bbeb-4cfa-932f-645a8aca8987&amp;name=structuralformula.jpg"></p>
<p><span class="Bold">Chemical Name: <br></span>3-Amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine hydrochloride
</p>
<p><span class="Bold">Each mL contains:  Active:</span> Epinastine HCl 0.05% (0.5 mg/mL) equivalent to epinastine 0.044% (0.44 mg/mL); <span class="Bold">Preservative:</span> Benzalkonium chloride 0.01%; <span class="Bold">Inactives:</span>  Edetate disodium; purified water; sodium chloride; sodium phosphate, monobasic; and sodium hydroxide and/or hydrochloric acid (to adjust pH). <span class="Bold">ELESTAT</span><span class="Sup">®</span> has a pH of approximately 7 and an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> range of 250 to 310 mOsm/kg.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s18"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s19"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Epinastine is a topically active, direct H<span class="Sub">1</span>-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H<span class="Sub">1</span>-receptor and has affinity for the histamine H<span class="Sub">2</span>-receptor. Epinastine also possesses affinity for the α<span class="Sub">1</span>, α <span class="Sub">2</span>-, and 5-HT<span class="Sub">2</span>–receptors.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s20"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Fourteen subjects, with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>, received one drop of <span class="Bold">ELESTAT</span><span class="Sup">®</span> ophthalmic solution in each eye twice daily for 7 days. On day 7, average maximum epinastine plasma concentrations of 0.04±0.014 ng/ml were reached after about two hours indicating low systemic exposure. While these concentrations represented an increase over those seen following a single dose, the day 1 and day 7 Area Under the Curve (AUC) values were unchanged indicating that there is no increase in systemic absorption with multiple dosing.  Epinastine is 64% bound to plasma proteins. The total systemic clearance is approximately 56 L/hr and the terminal plasma elimination half-life is about 12 hours. Epinastine is mainly excreted unchanged. About 55% of an intravenous dose is recovered unchanged in the urine with about 30% in feces. Less than 10% is metabolized.  The renal elimination is mainly via active tubular secretion.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s21"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s22"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">In 18-month or 2-year dietary carcinogenicity studies in mice or rats, respectively, epinastine was not carcinogenic at doses up to 40 mg/kg [approximately 30,000 times higher than the MROHD, assuming 100% absorption in humans and animals]. 
</p>
<p>Epinastine in newly synthesized batches was negative for mutagenicity in the Ames/<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> assay and <span class="Italics">in vitro</span> chromosome aberration assay using human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.  Positive results were seen with early batches of epinastine in two <span class="Italics">in vitro</span> chromosomal aberration studies conducted in 1980s with human peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and with V79 cells, respectively. Epinastine was negative in the <span class="Italics">in vivo</span> clastogenicity studies, including the mouse micronucleus assay and chromosome aberration assay in Chinese hamsters. Epinastine was also negative in the cell transformation assay using Syrian hamster embryo cells, V79/HGPRT mammalian cell point mutation assay, and <span class="Italics">in vivo</span>/<span class="Italics">in vitro</span> unscheduled DNA synthesis assay using rat primary hepatocytes.
</p>
<p>Epinastine had no effect on fertility of male rats. Decreased fertility in female rats was observed at an oral dose up to approximately 90,000 times the MROHD.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s23"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">Epinastine HCl 0.05% has been shown to be significantly superior to vehicle for improving <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> in patients with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span> in clinical studies using two different models:  (1) conjunctival antigen challenge (CAC) where patients were dosed and then received antigen instilled into the inferior conjunctival fornix; and (2) environmental field studies where patients were dosed and evaluated during <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> season in their natural habitat. Results demonstrated a rapid onset of action for epinastine HCl 0.05% within 3 to 5 minutes after conjunctival antigen challenge. Duration of effect was shown to be 8 hours, making a twice daily regimen suitable. This dosing regimen was shown to be safe and effective for up to 8 weeks, without evidence of <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s24"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First"><span class="Bold">ELESTAT</span><span class="Sup">®</span> (epinastine HCl ophthalmic solution) 0.05% is supplied sterile in opaque white LDPE plastic bottles with dropper tips and white high impact polystyrene (HIPS) caps as follows:
</p>
<p>5 mL in 10 mL bottle                  NDC 0023-9201-05
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s25"></a><a name="section-12.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 15º-25ºC (59º-77ºF). Keep bottle tightly closed and out of the reach of children.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s26"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-13.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip
</h2>
<p class="First">Patients should be advised not to touch dropper tip to any surface, as this may contaminate the contents (see <span class="Bold">WARNINGS AND PRECAUTIONS, <a href="#s6">5.1</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-13.2"></a><p></p>
<h2>17.2 Concomitant Use of Contact Lenses
</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. Patients should be advised that <span class="Bold">ELESTAT</span><span class="Sup">®</span> should not be used to treat contact lens-related irritation. Patients should also be advised to remove contact lenses prior to instillation of <span class="Bold">ELESTAT</span><span class="Sup">®</span>. The preservative in <span class="Bold">ELESTAT</span><span class="Sup">®</span>, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of <span class="Bold">ELESTAT</span><span class="Sup">®</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Topical Ophthalmic Use Only
</h2>
<p class="First">For topical ophthalmic administration only.
</p>
<p><span class="Bold">Rx only</span><br>© 2012 Allergan, Inc.<br>Irvine, CA  92612, U.S.A.<br>Allergan corporate signature logo is a registered trademark of Allergan, Inc.<br><span class="Bold">ELESTAT</span> is a registered trademark of Boehringer Ingelheim International GmbH and is licensed to Allergan, Inc. <br> Made in the U.S.A.
</p>
<p><a name="f02"></a><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9628ec7-bbeb-4cfa-932f-645a8aca8987&amp;name=allerganlogo.jpg"></p>
<p>72499US10
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s30"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">ALLERGAN</span> NDC 0023-9201-05
</p>
<p><span class="Bold Italics">Elestat</span><span class="Sup">®</span></p>
<p>(epinastine HCI
</p>
<p>ophthalmic solution) 0.05%
</p>
<p><span class="Bold">5 mL Rx only</span> sterile
</p>
<div class="Figure">
<a name="f03"></a><img alt="Bottle Label - 5 mL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9628ec7-bbeb-4cfa-932f-645a8aca8987&amp;name=label.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s31"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">ALLERGAN</span></p>
<p>NDC 0023-9201-05
</p>
<p><span class="Bold Italics">Elestat</span><span class="Sup">®</span></p>
<p>(epinastine HCl
</p>
<p>ophthalmic solution) 0.05%
</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">5 mL</span>   sterile
</p>
<div class="Figure">
<a name="f04"></a><img alt="Carton Label - 5 mL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9628ec7-bbeb-4cfa-932f-645a8aca8987&amp;name=carton.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELESTAT 		
					</strong><br><span class="contentTableReg">epinastine hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0023-9201</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>epinastine hydrochloride</strong> (epinastine) </td>
<td class="formItem">epinastine hydrochloride</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0023-9201-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021565</td>
<td class="formItem">01/19/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Allergan, Inc.
							(144796497)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan, Inc.</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e2252a1e-b2f8-40f3-98f5-eacd97fa8683</div>
<div>Set id: a9628ec7-bbeb-4cfa-932f-645a8aca8987</div>
<div>Version: 5</div>
<div>Effective Time: 20111202</div>
</div>
</div> <div class="DistributorName">Allergan, Inc.</div></p>
</body></html>
